BeOne Medicines AG (NASDAQ:ONC) highlighted significant progress in pipeline development at the 44th Annual J.P. Morgan Healthcare Conference. The company’s BRUKINSA achieved a 74% six-year progression-free survival rate in treatment-naïve chronic lymphocytic leukemia patients. Sonrotoclax, a BCL2 inhibitor, received regulatory approval with an 86% overall response rate in heavily pretreated CLL patients.

Citizens reiterated a Market Perform rating and a $396 price target for BeOne Medicines AG (ONC) on January 7. The company’s phase 3 trial data in gastric cancer patients impressed analysts. Sonrotoclax is expected to receive global approval, with Brukinsa estimated to generate $3.8 billion in 2025. The company is advancing 15 new molecular entities into clinical trials.

BeOne Medicines AG (NASDAQ:ONC) is a biotechnology company focused on developing innovative oncology treatments. Known for products like Brukinsa and Tevimbra, the company utilizes a global network for research and development. Wall Street is optimistic about the company’s robust pipeline development and potential for growth.

While BeOne Medicines AG (NASDAQ:ONC) shows promise as an investment, certain AI stocks may offer greater upside potential with lower downside risk. For those interested in undervalued AI stocks benefiting from current trends, explore our report on the best short-term AI stock. Check out 12 Best Consumer Goods Stocks Billionaires Are Quietly Buying and Goldman Sachs Penny Stocks: Top 12 Stock Picks for more insights.

Read more at Yahoo Finance: Wall Street Bullish on BeOne Medicines AG (ONC) amid Robust Pipeline Development